Pharmacotherapy in Psychiatry and Neurology
eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Reviewers Instructions for authors
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
2/2025
vol. 41
 
Share:
Send email
Share:
Review article

Withdrawal syndrome, discontinuation syndrome and rebound effect in the treatment with selected drug classes

Barbara Sobera
1
,
Mateusz Gadzała
1
,
Przemysław Mikołajczak
2
,
Dagmara Mirowska-Guzel
3

  1. Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland; Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Centrum Badań Przedklinicznych, Warszawski Uniwersytet Medyczny, Warszawa
  2. Department of Pharmacology, Poznań University of Medical Sciences, Poznań, Poland; Katedra i Zakład Farmakologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań
  3. Neurological Clinic, Institute of Psychiatry and Neurology, Warsaw; Poradnia Neurologiczna, Instytut Psychiatrii i Neurologii, Warszawa
Farmakoterapia w Psychiatrii i Neurologii 2025
DOI: https://doi.org/10.5114/fpn.2025.159504
Online publish date: 2026/04/28
Article file
- Withdrawal syndrome, discontinuation syndrome and rebound effect in the treatment with selected drug  [0.59 MB]
Get citation
 
PlumX metrics:
 
1. Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 1991; 8: 19-28.
2. Athavale A, Murnion B. Gabapentinoids: a therapeutic review. Aust Prescr 2023; 46: 80-85.
3. Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA et al. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr 2009; 67: 408-13.
4. Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005; 28: 301-18.
5. Barbosa Eyler GE, Utria Castro JV. Zolpidem dependence and withdrawal. A case report of generalized seizures. Rev Colomb Psiquiatr (Engl Ed) 2023; 52: 265-267.
6. Berridge V, Mars S. History of addictions. J Epidemiol Community Health 2004; 58: 747-50.
7. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Ther Adv Psychopharmacol 2021; 11: 20451253211032053.
8. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013; 27: 545-72.
9. Chen G, Lai S, Bao G, Ke J, Meng X, Lu S et al. Distinct reward processing by subregions of the nucleus accumbens. Cell Rep 2023; 42: 112069.
10. Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom 2017; 86: 189-219.
11. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J 2017; 17: 162-174.
12. Cosci F. Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: A case report and review of the literature. Personalized Medicine in Psychiatry 2017; 1–2: 81-84.
13. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom 2020; 89: 283-306.
14. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev 2015; 2015: CD009652.
15. De La Iglesia-Larrad JI, Barral C, Casado-Espada NM, De Alarcon R, Macia-Casas A, Vicente Hernandez B et al. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature. Psychiatry Res 2020; 284: 112660.
16. De Las Cuevas C, Sanz E, De La Fuente J. Benzodiazepines: more "behavioural" addiction than dependence. Psychopharmacology (Berl) 2003; 167: 297-303.
17. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006; CD005194.
18. Divljakovic J, Milic M, Timic T, Savic MM. Tolerance liability of diazepam is dependent on the dose used for protracted treatment. Pharmacol Rep 2012; 64: 1116-25.
19. Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapie 2016; 71: 575-578.
20. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom 2015; 84: 72-81.
21. Fluyau D, Hashmi MF, Charlton TE 2025. Drug Addiction. StatPearls. Treasure Island (FL).
22. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ 2017; 189: E747.
23. Gahr M, Schonfeldt-Lecuona C, Kolle MA, Freudenmann RW. Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry 2013; 46: 123-9.
24. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med 2011; 30: 22-60.
25. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013; 9: 155-62.
26. Gunther M, Valido A, Jiang S, Stern TA. Antihistamines: Indications, Interactions, and Adverse Effects. Prim Care Companion CNS Disord 2025; 27: 25f03958.
27. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int 2019; 116: 355-361.
28. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms - Authors' reply. Lancet Psychiatry 2019; 6: 562-563.
29. Horowitz MA, Framer A, Hengartner MP, Sorensen A, Taylor D. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data. CNS Drugs 2023; 37: 143-157.
30. Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv 2010; 48: 9-12.
31. Ishikawa H, Takeshima M, Ishikawa H, Ayabe N, Ohta H, Mishima K. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review. Neuropsychopharmacol Rep 2021; 41: 434-439.
32. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016; 3: 760-773.
33. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002; 1: 13-20.
34. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-95.
35. Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict 2019; 28: 55-62.
36. Lader M, Kyriacou A. Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Curr Psychiatry Rep 2016; 18: 8.
37. Lagisetty P, Garpestad C, Larkin A, Macleod C, Antoku D, Slat S et al. Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse. Drug Alcohol Depend 2021; 221: 108583.
38. Lander M, Bastiampillai T, Sareen J. Review of withdrawal catatonia: what does this reveal about clozapine? Transl Psychiatry 2018; 8: 139.
39. Lewis RG, Florio E, Punzo D, Borrelli E. The Brain's Reward System in Health and Disease. Adv Exp Med Biol 2021; 1344: 57-69.
40. Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes. Psychosomatics 1981; 22: 253-4.
41. Madsen, Marianne M, M S. Psychological dependence. EBSCO Research Starters 2024.
42. Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ 2020; 369: m1315.
43. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-80.
44. Nathan PE, Conrad M, Skinstad AH. History of the Concept of Addiction. Annu Rev Clin Psychol 2016; 12: 29-51.
45. O'Brien C. Addiction and dependence in DSM-V. Addiction 2011; 106: 866-7.
46. Olmedo R, Hoffman RS. Withdrawal syndromes. Emerg Med Clin North Am 2000; 18: 273-88.
47. Olver J, Burrows G, Norman T. Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors. CNS Drugs 1999; 171-177.
48. Otani K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994; 9: 131-3.
49. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 Suppl 4: 27-30.
50. Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs 2016; 30: 9-25.
51. Siwek M, Chrobak AA, Gorostowicz A, Krupa AJ, Dudek D. Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review. Pharmaceuticals (Basel) 2021; 14: 451.
52. Soyka M. Treatment of Benzodiazepine Dependence. N Engl J Med 2017; 376: 2399-2400.
53. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet 2020; 395: 1938-1948.
54. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73: 1002-8.
55. Stepnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules 2018; 23: 2087.
56. Szalavitz M, Rigg KK, Wakeman SE. Drug dependence is not addiction-and it matters. Ann Med 2021; 53: 1989-1992.
57. Tallarida RJ. Receptor discrimination and control of agonist-antagonist binding. Am J Physiol 1995; 269: E379-91.
58. Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM et al. Neural bases for addictive properties of benzodiazepines. Nature 2010; 463: 769-74.
59. Teixeira MZ. Rebound effect of modern drugs: serious adverse event unknown by health professionals. Rev Assoc Med Bras (1992) 2013; 59: 629-38.
60. Theilman SB, Christenbury MM. Hypomania following withdrawal of trazodone. Am J Psychiatry 1986; 143: 1482-3.
61. Torres-Lockhart KE, Lu TY, Weimer MB, Stein MR, Cunningham CO. Clinical Management of Opioid Withdrawal. Addiction 2022; 117: 2540-2550.
62. Van Leeuwen E, Van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021; 4: CD013495.
63. Verghese C, Deleon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996; 39: 135-8.
64. Volkow ND, Michaelides M, Baler R. The Neuroscience of Drug Reward and Addiction. Physiol Rev 2019; 99: 2115-2140.
65. Wang HY, Chou WJ, Huang TY, Hung CF. Acute dystonia resulting from abrupt bupropion discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 766-8.
66. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther 2018; 7: 233-248.
67. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. Am Fam Physician 2006; 74: 449-56.
68. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357-68.
69. Wislowska-Stanek A, Jarkiewicz M, Mirowska-Guzel D. Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders. Pharmacol Rep 2025; 77: 303-314.
70. Xie F, Liu B, Yang L, Huang J, Li B, Li Y. Zolpidem-related euphoria, addiction and detoxification: A case report and review of the literature. Medicine (Baltimore) 2024; 103: e40280.
71. Yee B, Looi JCL, Agaciak M, Allison S, Chan SKW, Bastiampillai T. Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review. East Asian Arch Psychiatry 2023; 33: 44-64.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.